Our science


Ceftriaxone-Induced Immune Hemolytic Anemia: In Vitro Reversal With Peptide Inhibitor Of Complement C1 (PIC1)

Case Rep Hematol. 2019 Jan 30;2019:4105653. doi: 10.1155/2019/4105653 eCollection 2019


We report a case of ceftriaxone-induced immune hemolytic anemia in a 10-year-old with chronic active Epstein-Barr virus disease and hemophagocytic lymphohistiocytosis. After chemotherapy, she became febrile and received ceftriaxone. She rapidly developed respiratory failure and anemia. Her direct antiglobulin test was positive for IgG and C3. To confirm this was ceftriaxone-induced complement-mediated hemolysis, we adapted the complement hemolysis using human erythrocytes (CHUHE) assay by adding exogenous ceftriaxone to the patient’s serum which enhanced lysis of her erythrocytes. We confirmed that ceftriaxone initiated a classical complement pathway-mediated hemolysis by in vitro reversal with peptide inhibitor of complement C1 (PIC1).

PMID: 30838143 PMCID: PMC6374879 DOI: 10.1155/2019/4105653

More Abstracts

Aug 20, 2020

Incompatible Erythrocyte Transfusion With Lipopolysaccharide Induces Acute Lung Injury...

Acute transfusion reactions can manifest in many forms including acute hemolytic transfusion reaction, allergic reaction and transfusion-related...

Read More
Mar 28, 2018

Inhibition of Immune Complex Complement Activation And Neutrophil Extracellular...

Abstract: Two major aspects of systemic lupus erythematosus (SLE) pathogenesis that have yet to be targeted therapeutically are immune complex-i...

Read More
Dec 31, 2019

Inhibition of Complement Activation, Myeloperoxidase, NET Formation And Oxidant...

A product of rational molecular design, PA-dPEG24 is the lead derivative of the PIC1 family of peptides with multiple functional abilities inclu...

Read More